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Identity 
Other names: ARA9, FKBP16, FKBP37, SMTPHN, 
XAP-2, XAP2 




The AIP gene is located on Chromosome 11 at 
67250505-67258579 (GRCh37/hg19). The AIP gene is 
composed of 6 exons and spans approximately 8.07 kb 
of genomic DNA. 
Transcription 
AIP gene encodes a 1250bp mRNA transcript. No 
splice variants have been identified. 
Pseudogene 
No pseudogene reported. 
Protein 
Description 
AIP protein consists of 330 amino acids with a 
molecular weight of 37 kDa. 
AIP belongs to the family of tetratricopeptide repeat 
(TPR) domain-containing proteins. It has three TPR-
domains which are important for protein-protein 
interactions and an α helix at the C-terminal region and 
a PPIase-like domain (FKBP-type) in the N-terminus. 
Expression 
AIP is expressed ubiquitously and found in various 
human tissues such as: heart, brain, lung, placenta, 
kidney, skeletal muscle, mouth mucosa, exocrine 
pancreas, salivary gland, stomach, parathyroid, tonsil, 
nerve, ovary, connective adipose tissue, spleen, 
thymus, prostate, testis, colon, leucocytes and pituitary 
(Kuzhandaivelu et al., 1996; Leontiou et al., 2008). 
Localisation 
Cytoplasm and nucleus. 
Function 
To date, several AIP interacting partners have been 
identified including HBV-X, EBNA-3, AhR, Hsp90, 
Hsc70, PDE4A5, PDE2A3, PPARα, TRβ1, Gα13, Gαq, 
TOMM20, RET, survivin and ERα, which may indicate 
that AIP is involved in various cellular pathways, 
however, the consequenses ot these interactions are not 
fully understood (Cai et al., 2011; Trivellin and 
Korbonits, 2011). 
Clinical and functional data supports its role as a 
tumour suppressor gene. Loss of heterozygosity (LOH) 
is found in AIP mutation positive tumours. Our lab has 
previously shown that over-expression of wild-type 
AIP in human fibroblast and pituitary cell lines reduced 
cell proliferation compared with the empty vector 
control in vitro whereas the mutant AIP loses this 
ability compared to the wild-type AIP (Leontiou et al., 
2008). AIP knockdown with siRNA also supports the 
tumour-suppressor role for AIP as it results in increased 
cell proliferation in GH3 cells (Heliovaara et al., 2009; 
Leontiou et al., 2008). 
Homozygous deletion of AIP is embryonically lethal 
due to cardiovascular developmental abnormalities and 
erythropoietic failure (Kang et al., 2011; Lin et al., 
2007), suggesting that AIP has a crucial role for cardiac 
development and for maintaining erythropoiesis in 
mice. Heterozygote deletion of the AIP gene lead to the 
development of growth hormone- and prolactin-
secreting pituitary adenomas (Raitila et al., 2010). 
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AIP is a molecular co-chaperone protein. The most 
studied partner is the nuclear xenobiotic receptor AhR 
(aryl hydrocarbon receptor). AIP regulates its sub-
cellular localization and degradation. AhR, also knw  
as dioxin receptor is a ligand activated transcription 
factor found in the cytoplasm as part of a multiprotein 
complex with Hsp90 (Perdew, 1988), AIP (Carver and 
Bradfield, 1997; Meyer et al., 1998) and p23 
(Kazlauskas et al., 1999). After binding to its ligand it 
is transported to the nucleus where it heterodimerizes 
with aryl hydrocarbon receptor nuclear translocator 
(ARNT). This complex then binds to DNA recognition 
sequences known as xenobiotic inducible response 
elements (XREs/DREs/AHREs) within the promoter 
region of specific genes, leading to the transcription of 
xenobiotic-metabolizing enzymes. However, there is 
conflicting data regarding the role of AIP on AhR 
function. Some findings suggested that AIP has a role 
in stabilising unliganded AhR in the cytoplasm (LaPres 
et al., 2000; Meyer and Perdew, 1999; Nukaya et al., 
2010), therefore AIP may play a positive role in AhR-
mediated signalling. In contrast, other studies have 
suggested that AIP has a negative effect on AhR 
transcriptional activity (Hollingshead et al., 2004; 
Pollenz et al., 2006; Pollenz and Dougherty, 2005). AIP 
has other functions related to the other interacting 
partners but it is currently not known how lack of AIP 
leads to pituitary tumorigenesis. 
Homology 
AIP shares 94% and 93% sequence identity with mouse 
and rat AIP respectively. 
Mutations 
Germinal 
Germline mutations of AIP are associated with familial 
isolated pituitary adenoma (FIPA). Approximately 20% 
of FIPA families and 13% of sporadic young (<30 
years) onset have somatotroph or lactotroph adenomas 
(Cazabat et al., 2007; Cazabat et al., 2012; Chahal et 
al., 2010; Daly et al., 2007; Leontiou et al., 2008; 
Tichomirowa et al., 2011; Vierimaa et al., 2006). Over 
50 pathogenic mutations have been identified including 
deletions, insertions, segmental duplications, nonsense, 
missense, splice-site and promoter mutations, as well as 
large deletions of whole exons or the entire AIP gene. 
Mutations are present throughout the whole length of 
the gene and disrupt the protein. Sixty five percent of 
known AIP variants result in a truncated protein. The 
majority of the missense mutations are typically 
clustered around the C-terminal part of the protein, 
appeared to be crucial for its biological function 
(Ozfirat and Korbonits, 2010). The most common 
mutation is found at residue 304, a mutational 'hotsp t' 
CpG site. Informations regarding AIP mutations and 
polymorphisms are available in a locus-specific 
mutation database, available at: 
http://aip.fipapatients.org/. 
Somatic 
Somatic mutations in AIP have not been found to date 
in sporadic pituitary adenomas. Somatic mutations in 
AIP have been investigated in colorectal cancers, breast 
cancers, prostate tumours (Georgitsi et al., 2007) as 
well as endocrine tumours (thyroid lesions, adrenal 
lesions, carcinoids, parathyroid lesions, 
paragangliomas, pancreatic endocrine tumours and 
adenocarcinoids) but no somatic mutations were found 
(Raitila et al., 2007; Tichomirowa et al., 2011). 
Implicated in 
Familial isolated pituitary adenoma 
(FIPA) and simplex pituitary adenoma 
cases with germline AIP mutation 
Note 
Familial isolated pituitary adenoma (FIPA) is an 
autosomal dominant disease with incomplete 
penetrance. Heterozygote germline mutations have 
been identified in the aryl hydrocarbon receptor 
interacting protein (AIP) gene in 20% of FIPA families. 
FIPA has been characterised in >200 families. Most of 
the FIPA families with AIP mutations presented 
somatotropinomas or somatomammotropinomas 
followed by prolactinomas as well as non-functioning 
adenomas and very rarely corticotroph or 
thyrotropinomas. Approximately, eighty five percent of 
AIP mutation positive FIPA patients have acromegaly 
and around fifty percent with AIP mutation positive 
somatotropinomas are associated with gigantism (Daly 
et al., 2010). Pituitary tumours in AIP mutation positive 
patients have larger, more aggressive, invasive 
tumours, most commonly sparsely granulated subtype 
which show a poor response to somatostatin analogues 
(Daly et al., 2010) and also have a younger age at 
disease onset (18-24 years) (Korbonits and Kumar, 
2012). 
Prognosis 
AIP mutation positive patients show younger mean age 
at diagnosis than sporadic pituitary cases. Decreased 
level of AIP has been correlated with tumour 
invasiveness in somatotropinomas (Kasuki Jomori de 
Pinho et al., 2011). Genetic screening is now able to 
stratify carrier subjects and help to diagnose the 
presymptomatic patients (Chahal et al., 2011). 
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